Literature DB >> 8668662

Atom level electrotopological state indexes in QSAR: designing and testing antithyroid agents.

R R Abou-Shaaban1, H A al-Khamees, H S Abou-Auda, A P Simonelli.   

Abstract

PURPOSE: To design antithyroid agents with less side effects, the electrotopological-state (E-state) indexes of thiourylene moiety (SN&S) was utilized as a guideline to develop five acrylic thiourylene-type compounds with reduced antioxidant property.
METHODS: These agents were synthesized and screened for antithyroid activity in rats using 125I-thiocyanate discharge technique. In addition, chemiluminescence studies on the activated polymorphonuclear leukocytes (PMNLs) were also conducted to reveal antioxidant properties of the tested compounds.
RESULTS: A linear relationship between the in vitro literature value of the formation constants of thiourylene-type compounds with iodine (Kc) and the SN&S was observed and utilized in designing those agents. At least one of the compounds (abouthiouzine) was found to have a potential value as an antithyroid agent. The relative efficacy of abouthiouzine [1-n-butyl-3(isonicotinamido)-2-thiourea], after equimolar dose, was 102% and 51.5% of that of propylthiouracil with respect to the rate of 125I-discharge and 125I-uptake, respectively. In addition, chemiluminescence studies on PMNLs revealed that abouthiouzine has slight oxidant property. Such properties may provide advantages in avoiding the iatrogenic hypothyroidism and antithyroid-induced immunological reactions.
CONCLUSIONS: The E-state approach provides guidelines to economize efforts and cost of designing new antithyroid drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8668662     DOI: 10.1023/a:1016049921842

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  An electrotopological-state index for atoms in molecules.

Authors:  L B Kier; L H Hall
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

2.  Further studies on the chemical nature of compounds which inhibit the function of the thyroid gland.

Authors:  E B ASTWOOD; A BISSELL; A M HUGHES
Journal:  Endocrinology       Date:  1945-12       Impact factor: 4.736

3.  Formation of molecular iodine during oxidation of iodide by the peroxidase/H2O2 system. Implications for antithyroid therapy.

Authors:  J F Lagorce; J C Thomes; G Catanzano; J Buxeraud; M Raby; C Raby
Journal:  Biochem Pharmacol       Date:  1991-12-11       Impact factor: 5.858

4.  The effects of antithyroid drugs on intercellular mediators.

Authors:  R Wilson; J H McKillop; M Travers; J Smith; E Smith; J A Thomson
Journal:  Acta Endocrinol (Copenh)       Date:  1990-05

5.  Mechanism of the inhibition of enzymatic halogenation by antithyroid agents.

Authors:  D R Morris; L P Hager
Journal:  J Biol Chem       Date:  1966-08-10       Impact factor: 5.157

6.  The acclumulation of 35 S-antithyroid drugs by the thyroid gland.

Authors:  B Marchant; W D Alexander; J H Lazarus; J Lees; D H Clark
Journal:  J Clin Endocrinol Metab       Date:  1972-05       Impact factor: 5.958

7.  Chemiluminescence of whole blood. 1. A simple and rapid method for the estimation of phagocytic function of granulocytes and opsonic activity in whole blood.

Authors:  T Tono-Oka; N Ueno; T Matsumoto; M Ohkawa; S Matsumoto
Journal:  Clin Immunol Immunopathol       Date:  1983-01

Review 8.  Antithyroid drugs.

Authors:  D S Cooper
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

9.  Mechanisms of thyroid peroxidase- and lactoperoxidase-catalyzed reactions involving iodide.

Authors:  R P Magnusson; A Taurog; M L Dorris
Journal:  J Biol Chem       Date:  1984-11-25       Impact factor: 5.157

10.  In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis.

Authors:  J R Wall; S L Fang; T Kuroki; S H Ingbar; L E Braverman
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.